Given our findings and the previously mentioned studies showing that those with AAT deficiency are more predisposed to severe disease and death from COVID-19, it is reasonable to surmise that AAT augmentation in those with severe AAT deficiency would be beneficial against COVID-19. The gene discussed is SERPINA1; the disease is alpha 1-antitrypsin deficiency.